Medical Crossfire®: Adverse Event Management Strategies to Maximize the Benefit of Novel Targeted Therapies for Patients With AML

Release Date: February 19, 2021
Expiration Date: February 19, 2022

Activity Overview

The Medical Crossfire^® is a PER^® signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirited discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders explore the current treatment landscape for patients with AML who are ineligible for intensive therapy. The faculty present cases that illustrate the diagnosis and management of key adverse events that are associated with the use of novel targeted therapies in patients with AML. This lively discussion will highlight adverse event management strategies that maximize the benefit of targeted therapies and optimize the care of your patients with AML.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Target Audience

This educational program is directed toward hematologists, medical oncologists, nurses, researchers, and investigators who treat or are interested in the treatment and management of acute myeloid leukemia. Other allied health care professionals, including nurse practitioners and physician assistants, involved in the treatment and management of patients with acute myeloid leukemia will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Outline best practices in the clinical management of AML along the disease continuum and in the context of risk stratification among patients with these malignancies
• Describe the adverse event profiles of therapeutic agents commonly used in the treatment of AML
• Develop plans for monitoring and managing treatment-related side effects, including tumor lysis syndrome, myelosuppression and infectious complications, differentiation syndrome, and veno-occlusive disease

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Chair

Naval G. Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Research Funding: AbbVie, Amgen, Astellas, Bristol Myers Squibb, Cardiff Oncology, Covance, Daiichi Sankyo, Forty Seven, Genentech, GlycoMimetics, Hanmi, ImmunoGen, Incyte, Karyopharm, Newave Pharmaceutical, Nohla Therapeutics, Novartis, Pfizer, Servier, Sobi, Sunesis Pharmaceuticals; Consultant: Alnylam Pharmaceuticals, Disc Medicine; Mitsubishi Tanabe Pharma, Recordati; Advisory/Consulting: AbbVie, Agios, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, ImmunoGen, Incyte, Jazz Pharmaceuticals, Karyopharm, Novartis, Otsuka, Pfizer, Sunesis; Other: AbbVie, Agios, Amgen, Astellas Bristol Myers Squibb, Cardiff Oncology, Celgene, Covance, Daiichi Sankyo, Forty Seven, Genentech, GlycoMimetics, Hanmi, ImmunoGen, Incyte, Jazz Pharmaceuticals, Karyopharm, Newave Pharmaceutical, Nohla Therapeutics, Novartis, Otsuka, Pfizer, Servier, Sobi.

Faculty

Courtney DiNardo, MD, MSCE
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AbbVie, Agios, Celgene, Daiichi Sankyo, ImmuneOne; Consultant: AbbVie, Agios, Celgene, Gilead, ImmuneOne, Novartis, Takeda; Stock/Shareholder: Notable Labs.

Brian Jonas, MD, PhD, FACP
Associate Professor of Medicine
Chair, Hematologic Malignancies Disease Team Committee
Division of Hematology and Oncology
University of California Davis School of Medicine
University of California Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant/Research Support (all to institution): AbbVie, Amgen, AROG Pharmaceuticals, Celgene, Daiichi Sankyo, F. Hoffmann-La Roche, Forma Therapeutics, Forty Seven, Genentech/Roche, GlycoMimetics, Hanmi, lncyte, Jazz Pharmaceuticals, Leadiant Biosciences, Pfizer, Pharmacyclics; Consultant: AbbVie, Genentech, GlycoMimetics, Jazz Pharmaceuticals, Takeda; Other support: AbbVie (travel reimbursement related to consulting).

Andrew Wei, MBBS, PhD
Professor and Clinical Hematologist
Department of Haematology
The Alfred Hospital/Monash University
Melbourne, Australia

Disclosures: Grant/Research Support: AbbVie, Amgen, AstraZeneca, Celgene/BMS, F. Hoffmann-La Roche, Novartis, Servier; Consultant: Servier; Other Support: AbbVie (Research Funding, Honoraria, Speakers Bureau, and Advisory Committee), Amgen (Research Funding, Honoraria, and Advisory Committee), Astellas (Honoraria and Advisory Committee), AstraZeneca (Research Funding, Honoraria, and Advisory Committee), Celgene/BMS - Research Funding, Honoraria, Speakers Bureau, and Advisory Committee, F. Hoffmann-La Roche (Grant and Non-Financial Support--Support of parent study and funding of editorial support), Genentech (Honoraria and Advisory Committee), Janssen (Honoraria and Advisory Committee), MacroGenics (Honoraria and Advisory Committee), Novartis (Research Funding, Honoraria, Speakers Bureau, and Advisory Committee), Pfizer (Honoraria and Advisory Committee), Servier (Consultancy, Research Funding, Honoraria, and Advisory Committee) Professor Andrew Wei is a former employee of the Walter and Eliza Hall Institute and receives a fraction of its royalty stream related to venetoclax.

The staff of Physicians’ Education Resource^®, LLC (PER^®), have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.